658 related articles for article (PubMed ID: 31088111)
1. Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy.
Monés J; Biarnés M;
Eur J Ophthalmol; 2020 Sep; 30(5):1082-1090. PubMed ID: 31088111
[TBL] [Abstract][Full Text] [Related]
2. Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden.
Bro T; Hägg S
Eur J Ophthalmol; 2021 Jan; 31(1):144-148. PubMed ID: 31642333
[TBL] [Abstract][Full Text] [Related]
3. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.
Ho VY; Yeh S; Olsen TW; Bergstrom CS; Yan J; Cribbs BE; Hubbard GB
Am J Ophthalmol; 2013 Jul; 156(1):23-28.e2. PubMed ID: 23664153
[TBL] [Abstract][Full Text] [Related]
4. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P
Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
[TBL] [Abstract][Full Text] [Related]
5. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
[TBL] [Abstract][Full Text] [Related]
6. INTRAVITREAL ZIV-AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 52-Week Results.
de Oliveira Dias JR; Costa de Andrade G; Kniggendorf VF; Novais EA; Takahashi VKL; Maia A; Meyer C; Watanabe SES; Farah ME; Rodrigues EB
Retina; 2019 Apr; 39(4):648-655. PubMed ID: 29232334
[TBL] [Abstract][Full Text] [Related]
7. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
[TBL] [Abstract][Full Text] [Related]
8. Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study.
Gale RP; Pearce I; Eter N; Ghanchi F; Holz FG; Schmitz-Valckenberg S; Balaskas K; Burton BJL; Downes SM; Eleftheriadis H; George S; Gilmour D; Hamilton R; Lotery AJ; Patel N; Prakash P; Santiago C; Thomas S; Varma D; Walters G; Williams M; Wolf A; Zakri RH; Igwe F; Ayan F
Br J Ophthalmol; 2020 Apr; 104(4):493-499. PubMed ID: 31383649
[TBL] [Abstract][Full Text] [Related]
9. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.
Brynskov T; Munch IC; Larsen TM; Erngaard L; Sørensen TL
Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab.
Narayan DS; Muecke J
Indian J Ophthalmol; 2015 Nov; 63(11):832-6. PubMed ID: 26669334
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration: 12-Month Safety and Efficacy Outcomes.
Chang AA; Broadhead GK; Hong T; Joachim N; Syed A; Schlub TE; Toth L; Peto T; Zhu M
Ophthalmic Res; 2015; 55(2):84-90. PubMed ID: 26637166
[TBL] [Abstract][Full Text] [Related]
12. INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Vazquez-Alfageme C; Nicholson L; Hamilton RD; Patel PJ
Retina; 2019 Apr; 39(4):664-669. PubMed ID: 29324593
[TBL] [Abstract][Full Text] [Related]
13. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967
[TBL] [Abstract][Full Text] [Related]
14. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
[TBL] [Abstract][Full Text] [Related]
15. Predicting visual outcomes in patients treated with aflibercept for neovascular age-related macular degeneration: Data from a real-world clinical setting.
Fulcher C; Hazel CA; Pacey I; Ali H; Ghanchi FD
Eur J Ophthalmol; 2020 May; 30(3):543-549. PubMed ID: 30935224
[TBL] [Abstract][Full Text] [Related]
16. Aflibercept for neovascular age-related macular degeneration.
Sarwar S; Clearfield E; Soliman MK; Sadiq MA; Baldwin AJ; Hanout M; Agarwal A; Sepah YJ; Do DV; Nguyen QD
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD011346. PubMed ID: 26857947
[TBL] [Abstract][Full Text] [Related]
17. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
[TBL] [Abstract][Full Text] [Related]
18. Fluctuations in Pigment Epithelial Detachment and Retinal Fluid Using a Bimonthly Treatment Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration.
Zinkernagel MS; Wolf S; Ebneter A
Ophthalmologica; 2016; 235(1):42-8. PubMed ID: 26540259
[TBL] [Abstract][Full Text] [Related]
19. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal Combined Aflibercept + Anti-Platelet-Derived Growth Factor Receptor β for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial.
Heier JS; Wykoff CC; Waheed NK; Kitchens JW; Patel SS; Vitti R; Perlee L; Chu KW; Leal S; Asmus F; Son V; Schmelter T; Brown DM
Ophthalmology; 2020 Feb; 127(2):211-220. PubMed ID: 31791663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
